These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 11598313)
21. Protective effects of clioquinol on human neuronal-like cells: a new formulation of clioquinol-loaded PLGA microspheres for Alzheimer's disease. Barcia E; Salama A; Fernández-Carballido A; Negro S J Drug Target; 2011 Sep; 19(8):637-46. PubMed ID: 20945972 [TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and distribution of clioquinol in golden hamsters. Bondiolotti G; Sala M; Pollera C; Gervasoni M; Puricelli M; Ponti W; Bareggi SR J Pharm Pharmacol; 2007 Mar; 59(3):387-93. PubMed ID: 17331342 [TBL] [Abstract][Full Text] [Related]
23. Stoichiometry and conditional stability constants of Cu(II) or Zn(II) clioquinol complexes; implications for Alzheimer's and Huntington's disease therapy. Ferrada E; Arancibia V; Loeb B; Norambuena E; Olea-Azar C; Huidobro-Toro JP Neurotoxicology; 2007 May; 28(3):445-9. PubMed ID: 17382398 [TBL] [Abstract][Full Text] [Related]
24. Therapeutic treatments for Alzheimer's disease based on metal bioavailability. Crouch PJ; Barnham KJ; Bush AI; White AR Drug News Perspect; 2006 Oct; 19(8):469-74. PubMed ID: 17160147 [TBL] [Abstract][Full Text] [Related]
25. Clioquinol attenuates zinc-dependent beta-cell death and the onset of insulitis and hyperglycemia associated with experimental type I diabetes in mice. Priel T; Aricha-Tamir B; Sekler I Eur J Pharmacol; 2007 Jun; 565(1-3):232-9. PubMed ID: 17434477 [TBL] [Abstract][Full Text] [Related]
30. Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease. Johansson P; Åberg D; Johansson JO; Mattsson N; Hansson O; Ahrén B; Isgaard J; Åberg ND; Blennow K; Zetterberg H; Wallin A; Svensson J Psychoneuroendocrinology; 2013 Sep; 38(9):1729-37. PubMed ID: 23473966 [TBL] [Abstract][Full Text] [Related]
31. Novel 8-Hydroxyquinoline Derivatives as Multitarget Compounds for the Treatment of Alzheimer's Disease. Prati F; Bergamini C; Fato R; Soukup O; Korabecny J; Andrisano V; Bartolini M; Bolognesi ML ChemMedChem; 2016 Jun; 11(12):1284-95. PubMed ID: 26880501 [TBL] [Abstract][Full Text] [Related]
32. Clioquinol: review of its mechanisms of action and clinical uses in neurodegenerative disorders. Bareggi SR; Cornelli U CNS Neurosci Ther; 2012 Jan; 18(1):41-6. PubMed ID: 21199452 [TBL] [Abstract][Full Text] [Related]
33. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758 [TBL] [Abstract][Full Text] [Related]
34. Trace element alterations in Alzheimer's disease: A review. Cilliers K Clin Anat; 2021 Jul; 34(5):766-773. PubMed ID: 33580904 [TBL] [Abstract][Full Text] [Related]
35. Cerebrospinal fluid levels of transition metals in patients with Alzheimer's disease. Molina JA; Jiménez-Jiménez FJ; Aguilar MV; Meseguer I; Mateos-Vega CJ; González-Muñoz MJ; de Bustos F; Porta J; Ortí-Pareja M; Zurdo M; Barrios E; Martínez-Para MC J Neural Transm (Vienna); 1998; 105(4-5):479-88. PubMed ID: 9720975 [TBL] [Abstract][Full Text] [Related]
36. Anticancer activity of the antibiotic clioquinol. Ding WQ; Liu B; Vaught JL; Yamauchi H; Lind SE Cancer Res; 2005 Apr; 65(8):3389-95. PubMed ID: 15833873 [TBL] [Abstract][Full Text] [Related]
37. Combined analysis of CSF betaA42 peptide and tau protein and serum antibodies to glycosaminoglycans in Alzheimer's disease: preliminary data. Briani C; Ruggero S; Naccarato M; Cagnin A; Ricchieri GL; Pasqui L; Pizzolato G; Battistin L J Neural Transm (Vienna); 2002 Mar; 109(3):393-8. PubMed ID: 11956959 [TBL] [Abstract][Full Text] [Related]
38. Clioquinol effects on tissue chelatable zinc in mice. Nitzan YB; Sekler I; Frederickson CJ; Coulter DA; Balaji RV; Liang SL; Margulis A; Hershfinkel M; Silverman WF J Mol Med (Berl); 2003 Oct; 81(10):637-44. PubMed ID: 12928783 [TBL] [Abstract][Full Text] [Related]
39. CSF tau markers are correlated with hippocampal volume in Alzheimer's disease. de Souza LC; Chupin M; Lamari F; Jardel C; Leclercq D; Colliot O; Lehéricy S; Dubois B; Sarazin M Neurobiol Aging; 2012 Jul; 33(7):1253-7. PubMed ID: 21489655 [TBL] [Abstract][Full Text] [Related]
40. Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers. Iqbal K; Flory M; Khatoon S; Soininen H; Pirttila T; Lehtovirta M; Alafuzoff I; Blennow K; Andreasen N; Vanmechelen E; Grundke-Iqbal I Ann Neurol; 2005 Nov; 58(5):748-57. PubMed ID: 16247771 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]